Abstract
Arterial calcification (AC) is a hallmark of many serious diseases, including atherosclerosis, chronic kidney disease, and diabetes. AC may also develop as a side-effect of therapy with anticoagulants, such as warfarin which is widely used for prophylaxis of thrombosis. In our studies, we established the relation between warfarin-induced AC and activation of enzyme transglutaminase 2 (TG2) and β-catenin signaling. We showed that TG2-specific inhibitor KCC-009 significantly attenuated the damaging effects of warfarin on arterial tissue. A similar protective effect was also achieved with a dietary bioflavonoid quercetin that inhibits TG2 and β-catenin signaling. We have shown that quercetin intercepts the chondrogenic transformation of vascular smooth muscle and also drastically attenuates calcifying cartilaginous metaplasia in another model of AC caused by genetic loss of matrix gla protein (MGP). These findings suggest that quercetin may be considered as a promising anti-AC therapeutic in the clinical settings of warfarin supplementation and MGP dysfunction. Further studies are required to test the efficacy of quercetin on other types of AC.
Keywords: Arterial calcification, transglutaminase 2, β-catenin, warfarin, quercetin.
Current Pharmaceutical Design
Title:New Therapeutic Approaches to Arterial Calcification Via Inhibition of Transglutaminase andβ-Catenin Signalin
Volume: 20 Issue: 37
Author(s): Mikhail Konoplyannikov and Maria Nurminskaya
Affiliation:
Keywords: Arterial calcification, transglutaminase 2, β-catenin, warfarin, quercetin.
Abstract: Arterial calcification (AC) is a hallmark of many serious diseases, including atherosclerosis, chronic kidney disease, and diabetes. AC may also develop as a side-effect of therapy with anticoagulants, such as warfarin which is widely used for prophylaxis of thrombosis. In our studies, we established the relation between warfarin-induced AC and activation of enzyme transglutaminase 2 (TG2) and β-catenin signaling. We showed that TG2-specific inhibitor KCC-009 significantly attenuated the damaging effects of warfarin on arterial tissue. A similar protective effect was also achieved with a dietary bioflavonoid quercetin that inhibits TG2 and β-catenin signaling. We have shown that quercetin intercepts the chondrogenic transformation of vascular smooth muscle and also drastically attenuates calcifying cartilaginous metaplasia in another model of AC caused by genetic loss of matrix gla protein (MGP). These findings suggest that quercetin may be considered as a promising anti-AC therapeutic in the clinical settings of warfarin supplementation and MGP dysfunction. Further studies are required to test the efficacy of quercetin on other types of AC.
Export Options
About this article
Cite this article as:
Konoplyannikov Mikhail and Nurminskaya Maria, New Therapeutic Approaches to Arterial Calcification Via Inhibition of Transglutaminase andβ-Catenin Signalin, Current Pharmaceutical Design 2014; 20 (37) . https://dx.doi.org/10.2174/1381612820666140212205059
DOI https://dx.doi.org/10.2174/1381612820666140212205059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology
Current Vascular Pharmacology New Developments in Anthracycline-Induced Cardiotoxicity
Current Medicinal Chemistry Supertargeted Chemistry: Identifying Relationships Between Molecular Structures and their Sub-Cellular Distribution
Current Topics in Medicinal Chemistry Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Risk Factors for Development of Heart Failure
Current Cardiology Reviews Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry An In-Silico Investigation of Anti-Chagas Phytochemicals
Current Clinical Pharmacology Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Caveolin-3: Its Importance in Muscle Function and Pathology
Current Genomics Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Phyto-glycosides as Therapeutic Target in the Treatment of Diabetes
Mini-Reviews in Medicinal Chemistry Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Heat Shock Paradox and a New Role of Heat Shock Proteins and their Receptors as Anti-Inflammation Targets
Inflammation & Allergy - Drug Targets (Discontinued) Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Beta-blockers in Intensive Care Medicine: Potential Benefit in Acute Brain Injury and Acute Respiratory Distress Syndrome
Recent Patents on Cardiovascular Drug Discovery Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design